Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
Eton Pharmaceuticals announces the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in the United States. The company offers a patient support program with $0 co-pay for eligible, commercially insured patients. Eton aims to capture a significant portion of the estimated $50 million annual Nitisinone market. The product is available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions.
The introduction of Nitisinone Capsules by Eton Pharmaceuticals represents a strategic move to penetrate the existing market for hereditary tyrosinemia type 1 (HT-1) treatments, which is currently valued at over $50 million annually. The decision to make this product available exclusively through Optime Care could be an effort to streamline distribution and ensure quality patient support, which is crucial for therapies targeting rare diseases.
By offering a $0 co-pay program, Eton is likely to increase patient access to Nitisinone, potentially expanding its market share. However, the financial sustainability of such a program should be monitored, as it may impact Eton's profit margins. The company's ability to capture a significant portion of the market will depend on the effectiveness of their commercial infrastructure and the perceived value of their patient support services.
HT-1 is an ultra-rare disease, with fewer than 500 patients in the U.S., which means the patient pool for Nitisinone is inherently limited. Eton's commitment to this niche market underscores the importance of orphan drugs in the pharmaceutical industry. The partnership with Optime Care indicates a tailored approach to patient management, which is a growing trend in the treatment of rare diseases.
Although the market size for Nitisinone is relatively small, the high costs typically associated with orphan drugs can make them profitable. The success of Eton's entry into this market will depend on the drug's efficacy, the company's ability to navigate insurance processes and their support in managing the strict dietary requirements associated with HT-1 treatment.
Investors will be interested in the potential revenue streams from Nitisinone, given the stated market size. The $0 co-pay initiative could be a significant investment in market penetration, but it's essential to analyze the long-term financial impact of this strategy on Eton's earnings. The company's stock price may react to the uptake of Nitisinone and the effectiveness of their commercial strategy.
It will be important to track Eton's quarterly financials to assess the impact of Nitisinone sales on their overall financial performance. The partnership with Optime Care may also result in operational efficiencies that could improve margins over time. However, any changes in insurance coverage or healthcare policy affecting rare disease treatments could pose risks to expected revenues.
02/02/2024 - 06:50 AM
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* --$50 million annually --
DEER PARK, Ill., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Please see important safety information below. Tyrosinemia type 1 is an ultra-rare condition that is estimated to impact fewer than 500 patients in the United States.
"Eton is committed to serving patients and families with the rarest of conditions. We are proud to make Nitisinone available to the hundreds of patients in the United States and offer full patient and provider support services. We believe that our existing commercial infrastructure and strong patient support services should help us capture a meaningful percentage of the estimated $50 million annual Nitisinone market,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
Nitisinone Capsules are available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions. Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals. The Eton Cares Program will provide $0 co-pays for all commercially insured patients*, as well as prescription fulfillment, insurance benefits investigation, educational support, and financial assistance for qualifying patients.
Clinicians seeking to prescribe Nitisinone Capsules can e-prescribe by selecting Optime Care as the pharmacy or fax in a patient referral form to 866-318-2990. Additional product details can be found on the product website, www.nitisinoneUS.com.
For questions regarding prescription fulfillment, please contact Optime Care at 1-844-397-0541.
*Restrictions, limitations, and/or eligibility requirements may apply
USE and IMPORTANT SAFETY INFORMATION
What is Nitisinone?
What is the most important information I should know about Nitisinone?
Inadequate restriction of tyrosine and phenylalanine intake can result in raising plasma tyrosine levels. Plasma tyrosine levels above 500 micromol/L may lead to eye signs and symptoms like corneal ulcers, corneal cloudiness, inflammation of the cornea (keratitis), pink eye (conjunctivitis), eye pain, and sensitivity to light (photophobia), intellectual disability and developmental delay or painful thickening of the skin (hyperkeratotic plaques) on the soles and palms. Your healthcare provider should not adjust Nitisinone dosage in order to lower the levels of tyrosine in the blood. Changes in blood profile
You may develop a reduction in the number of white blood cells, which form part of the immune system (leukopenia) and abnormally low levels of platelets, which help the blood to clot (severe thrombocytopenia). Do not take Nitisinone if:
you are allergic to Nitisinone or any other ingredients. Stop using Nitisinone and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of the face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat. Before taking Nitisinone, tell your doctor if you:
are pregnant or plan to become pregnant. Nitisinone may harm your unborn baby. Tell your doctor if you become pregnant or suspect you are pregnant during treatment with Nitisinone. are breastfeeding or plan to breastfeed. It is not known if Nitisinone passes into your breast milk. Talk to your doctor about the best ways to feed your baby during treatment with Nitisinone. are aged 65 and older. Your doctor may need to adjust the dose of Nitisinone based on your requirements. are taking other medicines since Nitisinone can interfere with their effect. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. What are the possible side effects of Nitisinone? 1% ) include high tyrosine levels, low platelets (thrombocytopenia) or white cells in the blood (leukopenia), and complaints related to the eyes, including pink eye (conjunctivitis), corneal cloudiness, inflammation of the cornea, eye pain and extreme sensitivity to light (photophobia), nosebleed (epistaxis), itching (pruritus), skin inflammation (exfoliative dermatitis), rash (maculopapular rash), dry skin and hair loss (alopecia).
For more detailed information, please see full Prescribing Information for more information. www.fda.gov/medwatch
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases. The Company currently has four FDA-approved rare disease products: ALKINDI SPRINKLE® , Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
Eton Pharmaceuticals announces the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in the United States.
The patient support program offers $0 co-pay for eligible, commercially insured patients.
The estimated market size for Nitisinone is $50 million annually.
Optime Care is the exclusive provider of Nitisinone Capsules.
For questions regarding prescription fulfillment, please contact Optime Care at 1-844-397-0541.
